Key Takeaways
- • Regal Healthcare Capital Partners closed RHCP IV at $610 million in total commitments, exceeding its $550 million target by $60 million and representing approximately 11% oversubscription.
- • The firm has now raised nearly $1.3 billion in aggregate commitments across four funds since 2018, demonstrating consistent institutional demand for lower-middle-market healthcare services exposure.
- • Fund IV attracted $575 million in external commitments alongside strong backing from both existing limited partners and new institutional investors, including endowments, foundations, asset managers, consultants, and public pension plans.
- • Regal targets equity investments of approximately $75 million per platform company in healthcare services businesses with $20–$100 million in revenue and $2–$10 million in EBITDA, maintaining focus on the lower-middle market.
- • Lazard served as exclusive placement agent and Kirkland & Ellis as legal counsel, underscoring the institutional-grade infrastructure supporting the fundraise.
Summary
Regal Healthcare Capital Partners announced the final close of its fourth flagship private equity fund, RHCP IV, securing $610 million in total commitments—surpassing its original $550 million target. The oversubscribed close reflects sustained institutional confidence in the New York-based firm's lower-middle-market healthcare services strategy and the quality of its deal sourcing and management capabilities.
The $610 million fund comprises approximately $575 million in external commitments and follows three preceding funds that have generated nearly $1.3 billion in aggregate capital since the firm's establishment in 2018. This fundraising progression demonstrates consistent market appetite for a focused, sector-specific lower-middle-market healthcare platform with disciplined investment criteria and proven operational execution.
Fund IV attracted a diversified investor base spanning both returning limited partners and new institutional capital. According to the firm, new commitments came from endowments, foundations, asset managers, consultants, and public pension plans, expanding Regal's geographic footprint and investor type diversity. This mix of institutional backing—particularly from pension plans and endowments—signals institutional validation of the healthcare services thesis and the firm's track record in value creation within this segment.
Regal's investment strategy focuses on healthcare services companies operating in the United States with typical platform equity checks of approximately $75 million. The firm targets businesses generating $20–$100 million in revenue and $2–$10 million in EBITDA, maintaining a disciplined lower-middle-market positioning that balances growth potential with operational maturity and cash generation. David Kim, MD, and Jon Santemma, General Partners at Regal, emphasized investor confidence in the team's strategy and opportunities ahead. Lazard acted as exclusive placement agent, while Kirkland & Ellis provided legal counsel, underscoring the institutional-caliber advisory support accompanying the transaction.
The $610 million fund comprises approximately $575 million in external commitments and follows three preceding funds that have generated nearly $1.3 billion in aggregate capital since the firm's establishment in 2018. This fundraising progression demonstrates consistent market appetite for a focused, sector-specific lower-middle-market healthcare platform with disciplined investment criteria and proven operational execution.
Fund IV attracted a diversified investor base spanning both returning limited partners and new institutional capital. According to the firm, new commitments came from endowments, foundations, asset managers, consultants, and public pension plans, expanding Regal's geographic footprint and investor type diversity. This mix of institutional backing—particularly from pension plans and endowments—signals institutional validation of the healthcare services thesis and the firm's track record in value creation within this segment.
Regal's investment strategy focuses on healthcare services companies operating in the United States with typical platform equity checks of approximately $75 million. The firm targets businesses generating $20–$100 million in revenue and $2–$10 million in EBITDA, maintaining a disciplined lower-middle-market positioning that balances growth potential with operational maturity and cash generation. David Kim, MD, and Jon Santemma, General Partners at Regal, emphasized investor confidence in the team's strategy and opportunities ahead. Lazard acted as exclusive placement agent, while Kirkland & Ellis provided legal counsel, underscoring the institutional-caliber advisory support accompanying the transaction.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.